We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


IonGate Biosciences and LIVC Technologies Establish Technology and Marketing Co-operation

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "IonGate Biosciences and LIVC Technologies Establish Technology and Marketing Co-operation"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

IonGate Biosciences GmbH and LIVC Technologies GmbH have announced a co-operation for joint development and marketing of the LIVC Technology.

LIVC is a proprietary technology that can initiate and measure voltage activated ion channels via light induction, which works similar to a remote control.

Until now, high-throughput activation and exploration of ion channels has only been possible in low quality. The so-called LIVC Technology (Light Induced Voltage Clamp) finally allows high-throughput screening of voltage activated ion channels without any loss of time or information.

Firstly, a light activated ion channel is entered into the target cells. Secondly, this ion channel is then opened via a light impulse. The activation of the ion channel leads to depolarization in turn activates the ion channels which are the targets of exploration. With LIVC, it is possible to switch on and off voltage activated ion channels under physiological conditions. Thus, the function of these ion channels in a living organism can be imitated.

The high potential of the LIVC Technology lies in the improvement of research methods in the pharmaceutical industry, for finding new, or optimizing existing, compounds that act directly on the voltage activated ion channels. With LIVC, pharmaceutical companies will be able for the first time to get high-quality information in high-throughput information on new drug candidates and their method of action.

However, the perspectives for LIVC in pharmaceutical research far exceed the high-throughput screening of new compounds. For example, scientists could study the complex network of neurons in the brain and thus can improve the diagnosis of diseases of the central nervous system.

IonGate Biosciences and LIVC Technologies have agreed to co-operate in the area of international marketing of the LIVC Technology. Further details of the agreement will be published at a later date.

IonGate will present the new technology to an international audience during the "Screening Targets & Ion Channel Targets" conference in Boston, USA, which will be held on the 10th and 11th of September 2007.